THYROCARE - Thyrocare Tech.
📢 Recent Corporate Announcements
Thyrocare Technologies Limited has scheduled an earnings conference call on Thursday, May 07, 2026, at 5:30 PM IST. The management team will discuss the audited financial results for the fourth quarter and the full financial year ended March 31, 2026. Senior leadership, including the CEO, CFO, and COO, will be present to address investor queries. This is a standard regulatory filing following the end of the fiscal year.
- Earnings call scheduled for May 07, 2026, at 5:30 PM IST to discuss Q4 and FY26 results.
- Management participants include MD & CEO Rahul Guha and CFO Vikram Gupta.
- Universal dial-in numbers for the call are +91 22 6280 1408 and +91 22 7115 8296.
- The call follows the conclusion of the audited financial period ending March 31, 2026.
Thyrocare Technologies has received a Notice of Demand under Section 156 of the Income-tax Act, 1961, for the Assessment Year 2024-25. The demand amount totals ₹2,02,82,260 and was issued by the Assessment Unit of the Income Tax Department. The company has clarified that this demand is litigative and they intend to contest it before the appropriate authorities within the prescribed timelines. Currently, the management believes there is no material impact on the company's operations or financial activities beyond the potential liability mentioned.
- Tax demand of ₹2,02,82,260 raised by the Income Tax Department.
- The notice pertains specifically to Assessment Year 2024-25.
- Company intends to contest the demand through an appeal or formal reply.
- Management states no immediate material impact on operations or financials.
- The notice was received by the company on March 28, 2026.
Thyrocare Technologies has announced the closure of its trading window for all designated persons effective April 1, 2026. This move is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations ahead of the company's financial results for the quarter and year ending March 31, 2026. The trading window will remain closed until 48 hours after the results are officially declared to the stock exchanges. This is a routine administrative filing and does not impact the company's fundamental business operations.
- Trading window closure starts from April 1, 2026, for all designated persons.
- Closure is in anticipation of the financial results for the quarter and year ending March 31, 2026.
- The window will reopen 48 hours after the financial results are announced to the exchanges.
- The specific date for the Board meeting to consider results will be announced separately.
Thyrocare Technologies has approved the allotment of 3,624 equity shares to employees who exercised their options under the company's ESOS. The allotment was finalized by the Nomination & Remuneration Committee on March 02, 2026. This exercise increases the total paid-up equity share capital from 15,91,61,691 to 15,91,65,315 shares. The new shares will rank equally with existing shares and are currently being processed for listing on the NSE and BSE.
- Allotment of 3,624 equity shares of face value Rs. 10 each under ESOS
- Total paid-up equity capital increased to Rs. 1,59,16,53,150
- Total number of outstanding shares increased to 15,91,65,315
- The dilution to existing shareholders is negligible at approximately 0.002%
Thyrocare Technologies has invested an additional USD 475,000 (approx. INR 4.33 Crores) into its subsidiary, Thyrocare Laboratories (Tanzania) Limited. This capital infusion was executed through Compulsorily Convertible Irredeemable Preference Shares (CCPS) to support working capital and business operations. The total investment in the Tanzanian venture now reaches approximately INR 10.02 Crores, against a board-approved limit of INR 15 Crores. While the subsidiary is scaling with a turnover of INR 1.84 Crores in 2025, it currently reports a negative net worth of INR 0.32 Crores.
- Additional investment of USD 475,000 (INR 4.33 Crores) via subscription to CCPS.
- Total cumulative investment in the Tanzanian subsidiary now stands at INR 10.02 Crores.
- Thyrocare Tanzania reported a turnover of INR 1.84 Crores for the year ended December 31, 2025.
- The company maintains a 57.25% equity stake and 100% CCPS holding in the joint venture.
- Board approval allows for a total investment of up to INR 15 Crores in one or more tranches.
Thyrocare reported a strong Q3 FY26 with consolidated revenue growing 18% YoY, led by a 20% surge in the pathology segment. The company processed 49.6 million tests, a 22% increase, and expanded its active franchisee base to a record 10,300 partners. While the core franchisee business grew 12%, the partnership and insurance segments saw robust growth of 39% and 70% respectively. Management also highlighted achieving Six Sigma quality standards and the appointment of new leadership to drive further expansion.
- Consolidated revenue grew 18% YoY, with the core pathology business increasing by 20%.
- Total tests processed rose 22% YoY to 49.6 million, serving 4.5 million patients (up 14% YoY).
- Active quarterly franchisee base reached an all-time high of 10,300, up from 9,165 in the previous year.
- Partnership business revenue jumped 39% YoY, while the pre-policy medical checkup segment grew 70%.
- Achieved Six Sigma quality benchmark with 3.2 complaints per million tests, a 43% YoY improvement.
Thyrocare Technologies has informed the exchanges that the audio recording of its post-results earnings conference call is now available. The call, held on January 28, 2026, focused on the company's financial performance for the quarter and nine-month period ending December 31, 2025. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations. Investors can access the recording on the company's investor relations website, with a written transcript expected to follow shortly.
- Earnings conference call held on January 28, 2026, at 5:30 P.M. IST.
- Covers financial results for the quarter and nine months ended December 31, 2025.
- Audio recording link made available on the company's official investor portal.
- Compliance disclosure under Regulation 30 of SEBI Listing Regulations.
- Written transcript of the earnings call to be shared with exchanges shortly.
Thyrocare Technologies has amended its Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons (PIT Code) following a board meeting on January 28, 2026. The revised code strictly defines 'Designated Persons' and 'Immediate Relatives' to prevent the misuse of Unpublished Price Sensitive Information (UPSI). It covers promoters, directors, and senior employees up to two levels below the CEO, including those in material subsidiaries. This update ensures the company remains compliant with the latest SEBI (Prohibition of Insider Trading) Regulations.
- Board approved the amended PIT Code on January 28, 2026, to align with SEBI regulations.
- Code applies to employees up to two levels below the CEO and those in material subsidiaries with a 10% turnover/net worth threshold.
- Defines 'Material Financial Relationship' as transactions involving 25% or more of a Designated Person's annual income.
- Introduces an 'Insider Trading Compliance Tool' to automate the monitoring and reporting of trades by insiders.
Thyrocare Technologies reported a strong performance for Q3 FY26, with consolidated revenue growing 18% YoY to ₹195.5 crore. The company's profitability saw a significant boost as Reported EBITDA rose 38% YoY to ₹57.6 crore and Profit After Tax (PAT) surged 47% to ₹27.9 crore. Operational metrics remained robust with a 22% increase in tests conducted (49.6 million) and a 14% rise in patient volume. While the radiology segment saw a 7% revenue decline due to strategic exits from non-profitable centers, the core pathology business and partnership segments (up 39%) drove overall growth.
- Consolidated Revenue increased 18% YoY to ₹195.53 crore, driven by 20% growth in standalone pathology.
- Reported EBITDA grew 38% YoY to ₹57.64 crore, with margins expanding from 25% to 29%.
- Net Profit (PAT) surged 47% YoY to ₹27.91 crore; excluding exceptional items, PAT grew 80% to ₹34.07 crore.
- Operational volume reached 49.6 million tests (+22% YoY) and 4.5 million patients (+14% YoY).
- Partnership revenue grew by 39% YoY, while the active franchisee base expanded by 12% to approximately 10,300.
Thyrocare Technologies reported a robust Q3 FY26 with consolidated revenue growing 18% YoY to ₹195.53 crore, primarily driven by a 20% growth in the pathology segment. Profit After Tax (PAT) jumped 47% YoY to ₹27.91 crore, while EBITDA increased by 38% YoY to ₹57.64 crore, reflecting strong operational efficiency. The company processed a record 49.6 million tests, marking a 22% YoY volume growth. Additionally, partnership revenue, including PharmEasy, saw a significant 39% YoY increase, further strengthening its market position.
- Consolidated revenue grew 18% YoY to ₹195.53 crore, led by 20% growth in Pathology.
- PAT surged 47% YoY to ₹27.91 crore; EBITDA rose 38% YoY to ₹57.64 crore.
- Test volumes increased by 22% YoY to 49.6 million tests processed in Q3.
- Partnership revenue (including PharmEasy) recorded robust 39% YoY growth.
- Achieved Six Sigma quality standards with complaints reduced to 3.2 per million tests.
Thyrocare Technologies reported a strong performance for the quarter ended December 31, 2025, with revenue from operations growing 19.6% YoY to ₹182.48 crore. Net profit increased by 36.9% YoY to ₹26.15 crore, even after accounting for an exceptional charge of ₹5.97 crore related to new labor code compliance and capital restructuring. The company successfully executed a 2:1 bonus issue during the quarter, which resulted in the allotment of over 10.61 crore new shares. For the nine-month period, the company has shown robust growth with a net profit of ₹105.23 crore compared to ₹73.96 crore in the previous year.
- Revenue from operations increased 19.6% YoY to ₹182.48 crore from ₹152.55 crore.
- Net Profit grew 36.9% YoY to ₹26.15 crore; 9M FY26 profit stands at ₹105.23 crore.
- Exceptional item of ₹5.97 crore includes ₹4.01 crore for gratuity adjustments under New Labour Codes.
- Successfully completed a 2:1 bonus share allotment on December 1, 2025, increasing paid-up capital to ₹159.16 crore.
- Restated Basic EPS for the quarter stands at ₹1.64 compared to ₹1.18 in the year-ago period.
Thyrocare Technologies has onboarded legendary actor Madhuri Dixit as its brand ambassador to strengthen its position in the preventive healthcare segment. The company aims to leverage her mass appeal to encourage routine health check-ups across its 10,000+ franchise network. In Q2FY26, Thyrocare processed over 53.3 million diagnostic investigations, demonstrating significant operational scale. This marketing push is intended to drive volume growth and improve brand recall in a highly competitive diagnostic market.
- Onboarded Madhuri Dixit as Brand Ambassador to boost brand trust and visibility across India.
- Processed 53.3 million+ diagnostic and screening investigations in Q2FY26.
- Operates an extensive network with a quarterly active franchise count of 10,000+.
- Strategic focus on shifting consumer behavior from reactive treatment to proactive health management.
Thyrocare Technologies has been honored with two prestigious awards at the 4th Edition of National Diagnostics Forum & Awards 2026. The company secured the titles of 'Best Diagnostic Lab Chain of the Year' and 'Patient-Centric Diagnostic Company of the Year'. These accolades, presented by Voice of Healthcare on January 21, 2026, validate the company's operational excellence and focus on affordable diagnostics. Such recognition enhances brand equity and market positioning in the competitive Indian diagnostic landscape.
- Received 'Best Diagnostic Lab Chain of the Year' award at the 4th National Diagnostics Forum & Awards
- Named 'Patient-Centric Diagnostic Company of the Year' for its focus on quality and affordability
- Awards were organized by Voice of Healthcare (VOH) and presented on January 21, 2026
- Recognition reflects the company's mission to provide accessible diagnostic services through innovation
Thyrocare Technologies Limited has scheduled a conference call for analysts and investors on Wednesday, January 28, 2026, at 5:30 PM IST. The management will discuss the company's unaudited financial results for the third quarter and nine months ended December 31, 2025. The call will be led by senior management, including MD & CEO Rahul Guha and CFO Vikram Gupta. This is a routine regulatory notification following the conclusion of the reporting period.
- Earnings conference call scheduled for January 28, 2026, at 5:30 PM IST
- Focus on Unaudited Financial Results for Q3 and 9M ended December 31, 2025
- Senior management participation includes MD & CEO Rahul Guha and CFO Vikram Gupta
- Universal dial-in numbers provided: +91 22 6280 1408 and +91 22 7115 8296
- Webcast and early registration links have been made available for participants
Thyrocare Technologies has informed the exchanges that its statutory auditor, M S K A & Associates, has converted from a partnership firm into a Limited Liability Partnership (LLP). The firm is now known as M S K A & Associates LLP with a new ICAI Firm Registration Number W101187. This change is purely administrative and does not involve any resignation or appointment of a new auditor. The company confirmed that there is no change in audit responsibilities or the ongoing engagement.
- Statutory Auditor M S K A & Associates converted to an LLP effective January 17, 2026
- New entity name is M S K A & Associates LLP with LLPIN ACT-3789
- ICAI Firm Registration Number updated from 105047W to W101187
- The conversion does not constitute a resignation or a new appointment of auditors
- Audit responsibilities and engagement remain uninterrupted and unchanged
Financial Performance
Revenue Growth by Segment
Pathology revenue grew 24% YoY in Q2 FY26, while the Radiology business saw a modest 3% YoY growth. Within Pathology, the Franchisee business grew 20% YoY (INR 125 Cr) and the Partnership business grew 35% YoY. The API PharmEasy Diagnostics segment grew 46% YoY. For FY2025, diagnostic testing services contributed 89.22% of total revenue with a growth rate of 20.71%.
Geographic Revenue Split
The company primarily operates in India, with a recent strategic foray into Africa through Thyrocare Laboratories (Tanzania) Limited, a 50% joint venture. Specific regional percentage splits within India are not disclosed, but the company is 'going deeper into India' with 10,100+ active franchisees.
Profitability Margins
Standalone gross margin improved to 71.6% in Q2 FY26, up 100 basis points YoY. Standalone net profit margin for FY2025 was 15.13% compared to 13.58% in FY2024. Consolidated net profit margin stood at 13.20% in FY2025.
EBITDA Margin
Standalone normalized EBITDA margin reached 36% in Q2 FY26, an improvement of 470 basis points YoY. Consolidated normalized EBITDA margin was 34.8% in Q2 FY26, with normalized EBITDA growing 49% YoY. FY2025 consolidated EBITDA margin was 27.69%.
Capital Expenditure
The company has an acquisition cap of INR 15-20 crore per deal, aligned to 12-month post-deal ROIC projections. It has invested heavily in cold chain logistics and a dedicated phlebotomy fleet of 1,900 personnel to support growth.
Credit Rating & Borrowing
The company is debt-free as of Q2 FY26. It maintains a strong liquidity position with net cash and cash equivalents (including short-term mutual funds) exceeding INR 190 crore on a consolidated basis.
Operational Drivers
Raw Materials
Reagents and diagnostic consumables (categorized as cost of materials consumed) represent approximately 28.4% of standalone revenue (INR 57.36 Cr cost against INR 202.23 Cr revenue in Q2 FY26).
Import Sources
Not specifically disclosed, though procurement is managed through volume-based negotiations with vendors to achieve savings.
Key Suppliers
Not disclosed by name, but the company leverages its high volumes to negotiate harder with vendors for procurement savings.
Capacity Expansion
The company processed 53.3 million tests in Q2 FY26 (up 21% YoY) and served 5 million patients (up 12% YoY). It is expanding its network by adding 100 to 150 net franchisees every month.
Raw Material Costs
Cost of materials consumed was INR 109.96 Cr for H1 FY26 compared to INR 90.71 Cr in H1 FY25. Gross margins improved by 101 basis points YoY due to procurement savings and operational efficiencies like reduced repeat rates and wastages.
Manufacturing Efficiency
Efficiency is driven by higher asset utilization in Pathology and a 'slab-based pricing model' that encourages franchisees to increase volumes to reach higher margin tiers.
Logistics & Distribution
The company employs a dedicated fleet of 1,900 phlebotomists and has invested heavily in cold chain logistics to ensure sample integrity, which differentiates it from competitors who route orders through franchises.
Strategic Growth
Expected Growth Rate
18-22%
Growth Strategy
Growth will be achieved by going deeper into India with a focused test menu, strengthening the franchise network (10,100+ active centers), expanding partnerships in insurance and 'ECG at home', and scaling the international foray into Africa. The company also uses a 'pay-for-performance' structure for franchisees to drive volume growth.
Products & Services
Pathology testing services, Radiology imaging, preventive healthcare packages (Aarogyam), and phlebotomy services.
Brand Portfolio
Thyrocare, Aarogyam, Nueclear Healthcare, Pulse Hitech, Think Health.
New Products/Services
Expansion of the Aarogyam portfolio and new partnership-led services like 'ECG at home' are expected to drive incremental growth. Pathology contributes 89% of current business.
Market Expansion
Targeting deeper penetration in India and international expansion in Africa (Tanzania). The company adds 100-150 franchisees monthly to expand its reach.
Market Share & Ranking
The company reports outperforming the pathology diagnostic industry, which grows at early-to-mid teen rates, while Thyrocare grows at high-teen to early 20% rates.
Strategic Alliances
Joint venture in Tanzania (50% stake); partnerships with API PharmEasy (46% growth) and insurance companies.
External Factors
Industry Trends
The diagnostic industry is evolving toward preventive healthcare (Aarogyam is 36% of pathology sales) and digital integration. Thyrocare is positioning itself as a low-cost, high-volume player with a dedicated phlebotomy fleet to capture the shift toward home collection.
Competitive Landscape
Competes with national diagnostic chains and local labs. Competitors are challenged by Thyrocare's slab-based pricing and integrated logistics.
Competitive Moat
Moat is built on cost leadership, a massive network of 10,100+ franchisees, and a unique dedicated phlebotomy fleet of 1,900 people. This scale allows for procurement savings that are difficult for smaller players to replicate.
Macro Economic Sensitivity
Sensitive to healthcare spending trends and government regulations. The company passed on GST benefits to customers but also received GST benefits, keeping margins stable.
Consumer Behavior
Shift toward preventive health (Aarogyam growing 16%) and home-based testing (Partnership business growing 35%).
Geopolitical Risks
Operational risks associated with the international foray into Africa, including changing laws and government policies in foreign jurisdictions.
Regulatory & Governance
Industry Regulations
Subject to the Companies Act 2013, SEBI regulations, and Ministry of Corporate Affairs guidelines. Compliance includes Internal Financial Controls (IFC) under Section 134(5)(e).
Taxation Policy Impact
The company follows Indian Accounting Standards (Ind AS). Effective tax rates are not explicitly detailed but PAT grew 82% YoY in Q2 FY26, outpacing revenue growth.
Legal Contingencies
The company monitors risks related to changing laws, rules, and government policies. Specific pending court case values are not disclosed in the provided documents.
Risk Analysis
Key Uncertainties
Seasonality (Q3 softness), potential failure of IT/technological systems, and risks associated with the nascent Radiology/molecular imaging business which is capex-intensive.
Geographic Concentration Risk
Primarily concentrated in India; expansion into Africa introduces new geographic and regulatory risks.
Third Party Dependencies
High dependency on franchisees and B2B partners (aggregators/insurance) for revenue generation.
Technology Obsolescence Risk
Introduction of new technologies could reduce demand for traditional pathology services; the company mitigates this by investing in digital transformation and automation.
Credit & Counterparty Risk
Bad debt recovery contributed to the 470 bps improvement in standalone normalized EBITDA margin in Q2 FY26, indicating active management of receivables.